Open randomized controlled clinical trial of Simhnaad Guggulu in the management of Janu Sandhigatavata w.s.r. to Osteoarthritis
DOI:
https://doi.org/10.61096/ijpar.v11.iss2.2022.155-166Keywords:
Sandhivata, Osteoarthritis, Simhnaad Guggulu, Yograj GugguluAbstract
Sandhivata or Sandhigatavata, a type of Vatavyadhi, is a degenerative disorder of the joints. It especially affects weight bearing joints like knee joint; hip joint etc. results in painful and restricted movement of the affected joint. The clinical presentation of Sandhivata closely mimics with the disorder called Osteoarthritis which is the second most common rheumatologic problem. A comparative clinical study was conducted at V.Y.D.S Ayurved Mahavidyalaya, Khurja to compare the efficacy of Simhnaad Guggulu with the well-established control drug Yograj Guggulu in the management of Janu sandhigatavata w.s.r. to Osteoarthritis. Defining to the benefits assessed both the drugs were found capable to enforce relief, but based on % of improvement and clinical assessment of result, it can be concluded that Control drug (Yograj Guggulu) was more effective than trial drug (Simhnaad Guggulu) in most of the sign and symptom of the disease at extremely significant level.